Epstein–Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones by Young, Paul et al.
Epstein–Barr virus nuclear antigen (EBNA) 3A
induces the expression of and interacts with a
subset of chaperones and co-chaperones
Paul Young, Emma Anderton, Kostas Paschos, Rob White
and Martin J. Allday
Correspondence
Martin J. Allday
m.allday@imperial.ac.uk
Department of Virology, Imperial College London, St Mary’s Campus, Norfolk Place, London
W2 1PG, UK
Received 30 August 2007
Accepted 9 December 2007
Viral nuclear oncoproteins EBNA3A and EBNA3C are essential for the efficient immortalization of
B cells by Epstein–Barr virus (EBV) in vitro and it is assumed that they play an essential role in
viral persistence in the human host. In order to identify cellular genes regulated by EBNA3A
expression, cDNA encoding EBNA3A was incorporated into a recombinant adenoviral vector.
Microarray analysis of human diploid fibroblasts infected with either adenovirus EBNA3A or an
empty control adenovirus consistently showed an EBNA3A-specific induction of mRNA
corresponding to the chaperones Hsp70 and Hsp70B/B9 and co-chaperones Bag3 and
DNAJA1/Hsp40. Analysis of infected fibroblasts by real-time quantitative RT-PCR and Western
blotting confirmed that EBNA3A, but not EBNA3C, induced expression of Hsp70, Hsp70B/B9,
Bag3 and DNAJA1/Hsp40. This was also confirmed in a stable, inducible expression system.
EBNA3A activated transcription from the Hsp70B promoter, but not multimerized heat-shock
elements in transient transfection assays, consistent with specific chaperone and co-chaperone
upregulation. Co-immunoprecipitation experiments suggest that EBNA3A can form a complex
with the chaperone/co-chaperone proteins in both adenovirus-infected cells and EBV-
immortalized lymphoblastoid cell lines. Consistent with this, induction of EBNA3A resulted in
redistribution of Hsp70 from the cytoplasm to the nucleus. EBNA3A therefore specifically induces
(and then interacts with) all of the factors necessary for an active Hsp70 chaperone complex.
INTRODUCTION
EBNAs 3A, 3B and 3C are three related Epstein–Barr virus
(EBV) latency-associated proteins that are expressed in
lymphoblastoid cell lines (LCLs) produced by in vitro
infection of primary B cells with EBV. Genetic analysis has
revealed that EBNA3A and EBNA3C are two of six latency-
associated genes that are essential for the creation of LCLs
(Maruo et al., 2003; Tomkinson & Kieff, 1992; Tomkinson
et al., 1993). EBNAs 3A, 3B and 3C are a related family of
nuclear proteins that have modest amino acid sequence
similarity; their genes have a similar structure (a short 59
exon followed by a long 39 exon), are arranged tandemly in
the genome and are transcribed from the common
promoter (Cp) (reviewed by Bornkamm & Hammer-
schmidt, 2001). The EBNA3 proteins are unable to bind to
DNA directly, but all three bind to a cellular DNA-binding
factor, CBF1/RBP-Jk (Robertson et al., 1996). EBNA3A
and EBNA3C repress transcription of the viral promoters
TP1 and Cp through interaction with RBP-Jk and can
inhibit EBNA2-mediated activation of these promoters
(Bain et al., 1996; Cludts & Farrell, 1998; Le Roux et al.,
1994). In addition, EBNA3A and EBNA3C have been
shown to repress transcription when targeted artificially to
a promoter through a Gal4 DNA-binding domain (Bain
et al., 1996; Cludts & Farrell, 1998). Repression by
EBNA3A and EBNA3C is probably associated with the
ability of both proteins to recruit repression complexes,
which can alter histone acetylation and/or methylation
(Hickabottom et al., 2002; Knight et al., 2003; Radkov et al.,
1999; Touitou et al., 2001). Both EBNA3A and EBNA3C
bind to CtBP1 (E1A C-terminal-binding protein), a highly
conserved co-repressor that is associated with gene
silencing (Chinnadurai, 2002; Hickabottom et al., 2002;
Touitou et al., 2001).
All of the available evidence suggests that the EBNA3
proteins should regulate transcription, and gene regulation
mediated by the EBNA3 proteins is unlikely to be limited
to viral promoters. As EBV is associated with B-cell growth
transformation and several lymphomas (Rickinson & Kieff,
2007), it has been predicted that EBNA3A and EBNA3C
also modulate cellular gene targets involved in cell survival
Supplementary methods and tables are available with the online version
of this paper.
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tion of bona fide cellular targets of EBNA3A have, to date,
been largely unsuccessful.
Here, we show that EBNA3A can upregulate a specific
subset of cellular gene targets, including the chaperones
Hsp70 and 70B/B9 and the co-chaperones Hsp40 and Bag3.
This upregulation was initially shown by microarray
analysis using recombinant adenoviruses expressing
EBNA3A, but was confirmed by real-time quantitative
(q) RT-PCR and Western blot analyses. Importantly,
EBNA3A also interacts with the same subset of chaperones
and co-chaperones at physiological levels in LCLs.
Consistent with the observed upregulation of Hsp70B
mRNA, EBNA3A has been found to activate transcription
of the Hsp70B promoter and to co-localize in the nucleus
with Hsp70 protein.
METHODS
Cell culture. DG75 cells (a Burkitt’s lymphoma-derived cell line) and
LCLs were grown in suspension with RPMI 1640 medium
(Invitrogen). IMR-90 cells (human fetal lung fibroblasts) were
maintained in Eagle’s minimum essential medium (Sigma). The
HEK-293A cell line is an immortalized line of primary human
embryonic kidney cells transformed by sheared human adenovirus
type 5 (Ad5) DNA. The E1A and E1B region of the adenoviral
genome, which complements in trans the deletion of the E1 region in
the recombinant adenovirus, is expressed in 293A cells. The p53-
negative human lung carcinoma cell line H1299 and 293A cells were
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen). All
media were supplemented with 10% fetal calf serum, penicillin/
streptomycin (100 U ml
21) and glutamine (2 mM).
Adenovirus construction. Adenovirus production utilized the
pAdEasy-1 system of recombinant adenoviruses (He et al., 1998;
Zeng et al., 2001). The system uses homologous recombination in
recA
+ Escherichia coli strain BJ5183 to introduce the gene of interest
into the adenovirus background. Initial cloning is performed into a
shuttle vector (p-Shuttle CMV) that has two regions of homology to
the adenovirus backbone plasmid (pAdEasy-1) and is devoid of E1
and E3. EBNA3A and the EBNA3A–CtBP binding mutant were
cloned from pcDNA3-HA-EBNA3A and pcDNA3-HA-EBNA3A–
CtBP, respectively [as detailed by Hickabottom et al. (2002), with
the CtBP-binding mutant described previously as the 26 mutant].
EBNA3C was cloned from a pcDNA3-EBNA3C vector via a
pBlueScript II SK+ cloning intermediate. Recombinant adenoviral
vectors were propagated in 293A packaging cells and scaled up before
CsCl purification and determination of the virus titre (for more
information, please refer to the Supplementary Methods, available in
JGV Online).
Microarray analysis. IMR-90 cells were infected (m.o.i. of 25) with
either adenovirus expressing EBNA3A or an empty adenovirus, which
served as a negative control. Virus infection was for 6 h before the
virus was removed and replaced with supplemented medium.
Microarrays compared adenovirus-EBNA3A with an empty control.
Total cell RNA was extracted 24 h post-infection with an RNeasy
Mega kit (Qiagen). Samples of the RNA were analysed by RNase-
protection assay for GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) content to ensure that the RNA was intact. RNA aliquots
(50 mg) from control and test cells were then labelled in reverse
transcription (RT) reactions with dCTP–Cy3 and dCTP–Cy5. Control
RNA labelled with Cy3 was mixed with test RNA labelled with Cy5,
and vice versa. Both mixes were used in overnight hybridization
reactions with Ludwig/Sanger/ICRF Consortium microarray chips
(Hver 2.1.1). The chips contained 15000 sequence-verified probes
(see http://www.sanger.ac.uk/Projects/Microarrays/ for more details
of the protocols). Labelling test samples with both Cy3 and Cy5
enabled us to minimize the variation within the experiment caused by
differential labelling with two different dyes. The slides were washed
and then scanned by using a GSI Lumonics ScanArray 4000 and
analysed by using QuantArray software. Three independent experi-
ments, with six chips per independent experiment (incorporating a
dye swap), were collated by using GeneSpring analysis software
(Silicon Genetics/Agilent). Data were Lowess-normalized.
Real-time qRT-PCR analysis. Primers for Bag3, Hsp70B/B9 and
Hsp40 (DNAJA1) were obtained from SuperArray (Tebu-Bio). The
primers for Hsp70B/B9 were not specific for either Hsp70B or B9, due
to the highly conserved nature of the gene sequence and lack of
introns (Leung et al., 1990). A Qiagen SYBR Green RT-PCR kit with
HotStarTaq DNA polymerase was used with an ABI Prism 7700
(Applied Biosystems). Real-time qRT-PCR conditions were RT for
30 min at 50 uC, using 250 ng RNA; melting for 15 min at 95 uC; and
30 cycles of three-step PCR, including melting for 30 s at 95 uC,
annealing for 30 s at 55 uC and elongation for 30 s at 72 uC. Melting-
curve analysis was performed to maintain single products and
products were verified by agarose-gel electrophoresis. GAPDH was
run as an endogenous control and all samples were normalized to
GAPDH levels before comparison of fold induction.
Immunoblotting and antibodies. RIPA cell lysates were prepared
and Western blotting was performed essentially as described
previously (Touitou et al., 2001). Membranes were blocked with
5% milk powder in PBS/0.05% Tween 20. After blocking,
membranes were probed with the following antibodies: anti-
Hsp70B9 (SPA756), anti-Hsp40 (SPA400), anti-Hsp90a (SPA771),
anti-Bag1 (AAM400) and anti-Hsp70 (SPA810) (all from Stressgen).
Anti-EBNA3C (A10) was a kind gift from Martin Rowe (Division of
Cancer Studies, University of Birmingham Medical School,
Birmingham, UK), anti-Bag3 was a kind gift from Alessandra Tosco
(Universita ` degli Studi di Salerno, Salerno, Italy) and polyclonal sheep
anti-EBNA3A was purchased from ExAlpha.
Immunoprecipitation (IP). IP was performed as described pre-
viously (Hickabottom et al., 2002; Radkov et al., 1997; Touitou et al.,
2005). Two hundred micrograms of protein in a final volume of
200 ml, diluted in IP lysis buffer, was used per IP. Protein G–
Sepharose beads were used to collect the immunoprecipitated
complexes and the beads were washed five times in IP lysis buffer
before SDS-PAGE for Western blot analysis.
B-cell isolation, culture and infection with EBV. Primary B cells
were isolated from mixed-donor platelet-depleted buffy-coat residues
by CD19 positive selection, as described previously (O’Nions &
Allday, 2004; Spender et al., 1999). Flow-cytometric analysis was
performed by using fluorescein isothiocyanate-conjugated anti-CD20
mAbs (Dako) to monitor cell purity. Purified B cells were found to be
between 80 and 90% pure. CD40 stimulation and infection with EBV
have been described previously (O’Nions & Allday, 2004; Spender
et al., 1999).
Inducible EBNA3A. The vectors for inducible expression of EBNA3A
and EBNA3A–CtBP mutant were made by cloning the haemagglu-
tinin (HA)-tagged versions of the wild-type gene and mutant into
expression vector pRTS1 [as described by Bornkamm et al. (2005), but
with a puromycin-resistance gene instead of hygromycin B] in place
of the luciferase gene. The resultant plasmids have an inducible,
bidirectional promoter driving the expression of EBNA3A or
EBNA3A–CtBP mutant in one direction and enhanced green
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gene EBNA1 and the EBV episomal origin of replication (oriP) and
are maintained episomally.
These plasmids and the parental RTS-1 (2 mg) were transfected into
H1299 cells with Lipofectamine 2000 as per the manufacturer’s
instructions (Invitrogen). Forty-eight hours after transfection, 1 mg
puromycin ml
21 (Calbiochem) was added. After 10 days, surviving
cells grown out were transferred into T25 flasks. Cells were induced
with 1 mg doxycycline ml
21 (Sigma) and eGFP was seen under a
microscope in 100% of cells after 24 h, indicating the presence of the
plasmid in all cells. Expression of EBNA3A and EBNA3A–CtBP
binding mutant was verified by Western blot.
Hsp70 immunofluorescence. H1299, H1299-RTS1 and H1299-3A
cells were seeded onto coverslips and incubated in the presence or
absence of 1 mg doxycycline ml
21 for 24 h. Cells were fixed with 4%
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100.
The coverslips were blocked in 1% BSA/PBS and incubated for 1 h at
37 uC with mouse monoclonal Hsp70 (SPA-810, 1:50) or mouse
monoclonal EBNA3A (a kind gift from Martin Rowe, used undiluted).
After washing in PBS, the slides were incubated with tetramethylrhoda-
mine isothiocyanate (TRITC)-conjugated goat anti-mouse secondary
antibody (1:100;Sigma). Slideswerewashed,MOWIOL-mounted and
visualized on a Zeiss LSM 510 META confocal microscope.
Transient transfections and b-galactosidase and reporter
assays. DG75 cells were transfected for reporter assays by
electroporation as described previously (Hickabottom et al., 2002),
typically with a total of 10 mg expression vector. IMR-90 cells were
transfected by using the LID transfection system, consisting of
Lipofectin reagent (Invitrogen), integrin-targeting peptide 6 (Hart et
al., 1998; White et al., 2003) and DNA (for more information on
transfection protocols and reporters, please refer to the
Supplementary Methods, available in JGV Online).
Transfected DG75 cells were harvested and lysed in 100 ml1 6
reporter lysis buffer (Promega) for 15 min. IMR-90 cells were lysed
on the plate for 15 min in 150 mlo f1 6 cell lysis reagent (Promega).
Twenty microlitres of cleared supernatant per transfection was used
in the luciferase assay or in the b-galactosidase assay, as described
previously (Hickabottom et al., 2002). All luciferase values were
normalized to b-galactosidase activity in the lysate.
RESULTS
Replication-defective adenoviruses (devoid of E1) expres-
sing EBNA3A (Ad-3A) or EBNA3C (Ad-3C) are shown
schematically in Fig. 1. A control adenovirus lacking an
inserted gene (Ad-E) was also produced. EBNA3A
expression was validated by immunofluorescence staining
(.70% cells were positive) and Western blotting (Figs 1
and 2d).
Microarray analysis shows that EBNA3A induces
all of the factors thought to be necessary for an
Hsp70 chaperone complex
Microarray analysis was used to compare the infection of
IMR-90 cells with Ad-3A or Ad-E. The data from
microarray analysis, 24 h post-infection, showed that
EBNA3A expression induced a specific subset of chaper-
ones and co-chaperones, including Hsp70, Hsp70B/B9,
Bag3 and Hsp40 (Table 1). This upregulation was
particularly significant given the small number of genes
induced in this system (n510; see Supplementary Tables S1
and S2, available in JGV Online, for a full list). The specific
subset of chaperones and co-chaperones induced by Ad-3A
are all part of an Hsp70 ATPase cycle (Fig. 2a). These
results suggest a co-ordinated regulation of a specific
pathway of the cell stress response by EBNA3A.
Real-time qRT-PCR and Western blot analysis
confirmed specific upregulation of Hsp70B/B§,
Bag3 and Hsp40 by EBNA3A
Real-time qRT-PCR experiments were performed to
validate the expression data obtained from the microarrays.
Aliquots of the RNA generated for microarray experiments
were combined with real-time qRT-PCR primers corres-
ponding to Bag3, Hsp40(DNAJA1) and Hsp70B/B9 (these
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Fig. 1. Schematic showing the pAdEasy-1
recombinant adenovirus backbone and the
EBNA3A and EBNA3C adenoviruses used in
this study. The CtBP-binding site(s) (A/V/
PLDLS) and predicted CBF1/RBP-Jk-binding
region are shown for EBNA3A and EBNA3C.
Immunofluorescence images of infected IMR-
90 cells (m.o.i. of 25, 24 h), using antibodies
specific for EBNA3A or 3C, are shown in the
bottom right panels. CMV, Cytomegalovirus;
LITR, left internal repeat; RITR, right internal
repeat.
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Comparison of Ad-3A- with Ad-E-infected IMR-90 cells
showed approximately 3-fold and 2-fold upregulation for
Bag3 and Hsp40, respectively (Fig. 2b). The observed
induction of the two co-chaperones was consistent with the
normalized microarray data (Table 1). Real-time qRT-PCR
results for Hsp70B/B9, comparing Ad-3A and Ad-E, gave
an approximately 400-fold upregulation. Hsp70B/B9 are
basic, heat-inducible forms of Hsp70 and have no mRNA
expression under normal physiological conditions.
However, cellular stresses, such as heat shock, are known
to induce Hsp70B9 mRNA (Leung et al., 1990). The
observed induction by EBNA3A was consistent with
Hsp70B/B9 being in an activated or ‘on’ state with
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Fig. 2. EBNA3A induces the co-chaperones necessary for the
ATPase cycle of Hsp70. (a) The Hsp70 family is one of the most
highly conserved gene families and consists of both constitutive
and inducible forms. Hsp70 has a dual function and can either form
a complex with a nascent or misfolded protein and chaperone them
for refolding, or remove proteins by polyubiquitination and
proteasome-mediated degradation (Bukau & Horwich, 1998;
Esser et al., 2004). Protein binding by Hsp70 is linked intrinsically
to its ATP/ADP-binding status, modulated through the N-terminal
ATPase domain (Greene et al., 1995; McCarty et al., 1995;
Palleros et al., 1993). Co-chaperones have been identified that
can regulate the peptide-binding cycle of Hsp70, by either
augmenting or inhibiting protein binding, or by targeting the
chaperone to a specific subcellular compartment or protein
(reviewed by Mayer, 2005). The co-chaperones Hsp40 and
Bag3 (shown in bold) were shown to be upregulated by
EBNA3A expression following adenovirus infection of IMR-90
cells. (b) Summary of real-time qRT-PCR analysis using all of the
RNA samples from Ad-3A versus Ad-E microarray experiments.
GAPDH was run as an endogenous control against which all
samples were normalized. (c) End-point real-time qRT-PCR
samples were resolved on an agarose gel, demonstrating little to
no Hsp70B/B9 DNA product with Ad-E infection. This is consistent
with Hsp70B/B9 being silent in most cells. NTC, No template
control; NAC, no activation (no reverse transcriptase) control. (d)
Western blot analysis of protein samples taken at the time of cell
harvesting for the microarray experiments (Table 1). A represent-
ative series of blots from one set of protein samples is shown,
probed with the antibodies indicated.
Table 1. Chaperone and co-chaperone subset of normalized
microarray data
Values are fold induction of RNA in Ad-3A-infected IMR-90 cells
compared with cells infected with the control empty adenovirus,
Ad-E. All adenovirus infections were at an m.o.i. of 25 for 24 h before
harvesting. Microarrays were performed with Sanger Hver2.1.1,
containing 15000 spotted human cDNA probes. All values are results
of three independent experiments with six chips in total per
experiment (with an incorporated dye swap). Microarray data have
been Lowess-normalized.
Probe* Ad-3A vs Ad-E
Normalized SD t-test P value
Hsp70 (HspA1A) 2.202 0.784 5.44610
26
Hsp70B/B9 (HspA6/7) 5.933 2.528 2.28610
27
2.623 1.102 8.86610
26
Bag3 3.470 1.935 4.63610
25
3.221 1.273 1.04610
26
Hsp40 (DNAJA1) 2.061 0.810 3.49610
25
*There are two probes corresponding to Hsp70B9 and Bag3, but only
one probe for Hsp70 (HspA1A) and Hsp40 (DNAJA1), because of
redundancy of some probes on Sanger Hver2.1.1 chips.
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with the control adenovirus. Agarose-gel analysis of the
end products of a representative real-time qRT-PCR
experiment showed little to no signal with Ad-E, but clear
Hsp70B/B9 transcript signal with Ad-3A (Fig. 2c).
To determine whether the increase in RNA was reflected in
the accumulation of protein, Western blot analysis was
performed on protein samples taken at the time of RNA
harvesting for microarray analysis (Fig. 2d). Representative
protein samples showed that the levels of chaperones
Hsp70 (HspA1A) and Hsp70B9 (HspA6) and of the co-
chaperones Hsp40 and Bag3 were increased when Ad-3A-
infected IMR-90 cells were compared with Ad-E-infected
control cells. Importantly, Hsp70B9 was undetectable when
IMR-90 cells were infected with Ad-E, but induced to a
high level when Ad-3A was expressed. These results are
consistent with the RNA data described above.
EBNA3C does not induce chaperone or
co-chaperone RNA or protein
The specificity of the induction of chaperones and co-
chaperones by EBNA3A was confirmed by comparison of
the above-described results with the responses obtained
when IMR-90 cellswere infected with Ad-3C, which encodes
the related protein EBNA3C. The results obtained with Ad-
3CwerecomparabletothosewithAd-E,i.e.failuretoinduce
expression of Bag3, Hsp40 or Hsp70B/B9, as shown by real-
time qRT-PCR analysis (Fig. 3a). Western blot analysis of
IMR-90 cells infected with Ad-3C compared with Ad-E-
infected control cells confirmed that EBNA3C was expressed
at a similar level to EBNA3A, but that it did not induce any
of the chaperones or co-chaperones (Fig. 3b).
EBNA3A and a subset of chaperones and co-
chaperones interact in cells
Experiments were performed to determine whether
EBNA3A and the upregulated chaperones and co-chaper-
ones interact in IMR-90 cells. In these experiments, the
double EBNA3A–CtBP binding mutant [as described by
Hickabottom et al. (2002)] was included, as CtBP binding
is important in gene regulation and protein–protein
interactions. Protein extracts from Ad-3A- or Ad-3A–
CtBP-infected IMR-90 cells were subjected to IP with
antibodies directed against Hsp70, Hsp70B9, Hsp40 or
Hsp90a, or an irrelevant antibody control, and subse-
quently Western-blotted and probed with an anti-EBNA3A
polyclonal antibody. Representative results shown in Fig. 4
demonstrate that both EBNA3A and the EBNA3A–CtBP
binding mutant co-precipitate with Hsp70, Hsp70B9 and
Hsp40, but not with Hsp90a or the control antibody. As
expected, the Ad-3A–CtBP binding mutant failed to co-
immunoprecipitate with endogenous CtBP. Reprobing the
membrane with an antibody specific for Hsp70 (HspA1A)
revealed the reverse co-IP of EBNA3A with Hsp70, using
an anti-EBNA3A IP and anti-Hsp70 Western blot.
Reprobing the filter further established that IP with anti-
Hsp40 resulted in precipitation of both Hsp70 and
EBNA3A, as shown by the representative Western blots.
Hsp40 interaction with Hsp70 has been shown previously
(Demand et al., 1998), but the presence of EBNA3A with
Hsp70 and Hsp40 suggests a chaperone–co-chaperone
ternary complex. The interaction of Ad-3A (and the CtBP
binding mutant) with chaperones and co-chaperones was
in contrast to that of Ad-3C, which failed to co-
immunoprecipitate the same endogenous chaperones and
co-chaperones in IMR-90 cells (data not shown).
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Fig. 3. No increase in chaperones or co-
chaperones was observed after infection with
adenovirus EBNA3C. (a) Real-time qRT-PCR
analysis with primers for Bag3, Hsp40 and
Hsp70B/B9. No significant increase in Bag3,
Hsp40 or Hsp70B/B9 was observed with Ad-
3C (m.o.i. of 25, 24 h) compared with Ad-E
control infection (Ad-3A infection results are
included for comparison). GAPDH is run as an
endogenous control to which all samples are
normalized. (b) Western blot analysis of
protein samples taken from IMR-90 cells
infected with Ad-3C versus Ad-E control
infection. No increase in chaperones or co-
chaperones was seen with EBNA3C expres-
sion.
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co-chaperones co-precipitate in LCLs, and
Hsp70B§ is upregulated in these cells
LCLs express the complete repertoire of EBV latent
proteins at their physiologically appropriate levels. LCLs
were initially Western-blotted to determine whether the
chaperones and co-chaperones were expressed.
Comparison of resting primary CD19
+ B cells, primary
B cells stimulated with CD40L/interleukin-4 (IL-4) for 1
and 2 weeks, similar B cells infected with EBV for 2 weeks
and established LCLs (LCL-BF and LCL-ED) demonstrated
the presence of endogenous chaperones and co-chaperones
in all of these B cells. It was noted that Hsp70B9 was
undetectable in primary resting B cells and was expressed at
a low level in CD40L/IL-4-stimulated B cells, but
expression was increased significantly in primary B cells
infected with EBV and in established LCLs (Fig. 5a). The
upregulation of Hsp70B9 in EBV-infected primary B cells
and LCLs was confirmed by real-time qRT-PCR analysis.
The amount of Hsp70B/B9 mRNA was 4–5-fold higher in
ED-LCLs than in primary B cells stimulated to proliferate
by CD40L/IL-4 (Fig. 5b).
Similar co-IP experiments to those described in Fig. 4 were
performed by using LCL extracts (Fig. 5c). EBNA3A in ED-
LCL co-immunoprecipitated with Hsp70B9, Hsp40 and
Bag3, but not with Hsp90a. The observed interactions
were weak, but were significantly above the background
produced by a non-specific antibody and were reproduced
in a second independent LCL (data not shown). Again,
the interaction was specific for EBNA3A; EBNA3C failed
to interact with any of the chaperones and co-chaperones
in LCLs (data not shown). These results confirmed
that EBNA3A interacts with specific chaperones and co-
chaperones even when it is expressed at its physiologically
functional level in EBV-immortalized B cells.
EBNA3A induces Hsp70, Hsp70B§ and Hsp40 in an
adenovirus-free inducible system and EBNA3A
expression results in a cytoplasm to nucleus shift
of Hsp70
To exclude the possibility that an interaction between
EBNA3A and adenovirus proteins produced the co-
ordinated upregulation of chaperone/co-chaperone pro-
teins, an inducible system was used. H1299 cells stably
transfected with tetracycline-inducible EBNA3A or
EBNA3A–CtBP binding mutant were induced with doxy-
cycline and incubated for 24 h to allow efficient protein
expression before subsequent Western blot analysis
(Fig. 6a). EBNA3A and the EBNA3A-CtBP binding mutant
similarly activated Hsp70, Hsp70B9 and Hsp40, although
Hsp40 upregulation in general was to a lower extent, due to
higher endogenous protein levels. This activation was not
due to the effects of doxycycline alone, as H1299 control
cells, with and without the addition of doxycycline, showed
no difference in chaperone/co-chaperone levels; nor was
the upregulation due to the presence of the RTS-1 GFP-
expressing plasmid backbone, as H1299-RTS1 control cells
treated with doxycycline showed no difference in chaper-
one levels (data not shown). Importantly, the levels of heat-
shock protein upregulation by EBNA3A are similar to the
levels following heat shock for approximately 12 h (Fig. 6b).
If EBNA3A and the Hsp70 complex interact, this suggests
that they must occupy the same cellular location. To test
this, the distribution of Hsp70 with and without the
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Fig. 4. EBNA3A binds to Hsp70, Hsp70B9
and the co-chaperone Hsp40 in adenovirus-
infected IMR-90 cells. IP from adenovirus-
infected IMR-90 cells (m.o.i. of 25, 24 h) using
Ad-3A, Ad-3A–CtBP binding mutant and
endogenous chaperones and co-chaperones.
EBNA3A or EBNA3A–CtBP were co-precipi-
tated with an anti-Hsp70, anti-Hsp70B9 or
anti-Hsp40 antibody and detected by Western
blot analysis with an anti-EBNA3A antibody.
No binding to Hsp90a was observed. Two
hundred micrograms of cell lysate was used
per IP and all antibodies were used at a 1:100
dilution, except anti-CtBP, which was used at
a 1:200 dilution. Hsp70 antibody was subse-
quently used to reprobe the membrane and is
shown below the respective EBNA3A
Western blots. RaM, Rabbit anti-mouse anti-
body; RaHsp40, rabbit anti-Hsp40;
RaHsp90a, rabbit anti-Hsp90a;R aHsp70B9,
rabbit anti-Hsp70B9;S a3A, sheep anti-
EBNA3A; RaCtBP, rabbit anti-CtBP; MaHA,
mouse anti-haemagglutinin; MaHsp70, mouse
anti-Hsp70.
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immunofluorescence. EBNA3A expression resulted in the
redistribution of Hsp70 from the cytoplasm to the nucleus
(Fig. 6c). Control cells consistently showed a predomi-
nantly cytoplasmic localization of Hsp70 in the absence of
EBNA3A expression.
EBNA3A and the CtBP binding mutant both
activate transcription of an Hsp70B promoter
In order to determine whether EBNA3A activates a heat
shock-responsive promoter directly, transient transfections
and luciferase assays were performed. These experiments
were conducted initially in IMR-90 cells using an Hsp70B
luciferase promoter (pGL3-Hsp70B) together with
EBNA3A, EBNA3A–CtBP binding mutant or EBNA3C
expression vectors (Fig. 7a). Transfection with increasing
amounts of EBNA3A plasmid DNA (and the CtBP binding
mutant) activated the Hsp70B promoter up to 70–80-fold
more than transfection with empty vector alone. In
contrast, EBNA3C failed to activate Hsp70B when similar
amounts of plasmid were used.
Similar transfections were performed in DG75 Burkitt’s
lymphoma-derived B cells. The results shown in Fig. 7(b)
revealed that both EBNA3A and the CtBP binding mutant
activated Hsp70B by approximately 6-fold with 10 mg
DNA. This was in contrast to EBNA3C, which failed to
activate transcription of Hsp70B. DG75 cells were observed
to have a higher background of Hsp70B promoter activity
compared with IMR-90 cells, which have a very low basal
activity. High basal activity of the heat-shock genes is
common in grossly transformed cell lines (Calderwood et
al., 2006) and may in part explain the observed reduced
activation when the general level of EBNA3A activation of
Hsp70B is compared between DG75 and IMR-90 cells. It
should be noted that although HA-tagged EBNA3A was
used in all of the transient transfection experiments shown
here, similar experiments using an untagged EBNA3A
expression vector produced the same level of activation
(data not shown).
These results suggest that EBNA3A can upregulate Hsp70B
through transcriptional activation and that the loss of the
ability of EBNA3A to bind CtBP has no effect on promoter
activation. Activation is specific for EBNA3A, as EBNA3C
has no effect on the Hsp70B promoter.
EBNA3A (and the EBNA3A–CtBP binding mutant)
can activate Hsp70B transcription from a
truncated Hsp70B promoter, but not from
multimerized heat-shock elements (HSEs) or
AP1-binding sites
Hsp70B promoter sequence analysis and transcription
factor-binding site prediction (using a promoter extending
1318 bp upstream of the transcription start site and
transcription binding-site analysis tools available at http://
www.cbrc.jp/research/db/TFSEARCH.html) revealed a num-
ber of HSEs (Fig. 7c). Heat shock results in the activation of
heat-shock factors (HSFs), which, through a process of
trimerization and nuclear translocation/localization, results
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binding to HSEs (reviewed by Morimoto, 1998). To
determine the minimal promoter region required for
EBNA3A-mediated activation of Hsp70B, promoter trunca-
tions were produced (Fig. 7c). Truncation to a 1080 bp
promoter (removing the 59 distal HSE) and further
truncation to a 467 bp fragment both resulted in a response
similar to that of the full-length Hsp70B promoter. The
remaining promoter element contained four HSE sites and,
in addition, two predicted AP1-binding sites (Fig. 7c).
Luciferase reporter assays using promoter elements with
either multimerized HSEs or AP1-binding sites were
performed; however, neither was activated significantly
following co-transfection with EBNA3A (Fig. 7d). These
data suggest a mechanism for Hsp70B activation that is
independent of HSF activation of HSEs and of the binding of
factors to AP1 sites.
DISCUSSION
Our studies using recombinant adenoviruses have demon-
strated that the EBV oncoprotein EBNA3A can specifically
coordinate the induction of Hsp70 chaperones and a
specific subset of associated co-chaperones. Adenovirus
expressing the closely related EBNA3C consistently failed
to induce any of the chaperones or co-chaperones tested.
Furthermore, the induction by EBNA3A is independent of
any synergy between EBNA3A and adenovirus-encoded
proteins, as activating EBNA3A expression in a stable,
inducible system produced similar results.
By using Hsp70B as a representative heat-shock stress-
inducible promoter, EBNA3A (but not EBNA3C) can
activate transcription. Hsp70B-truncation experiments high-
lighted a minimal promoter region through which tran-
scription activation was induced by EBNA3A. This promoter
region contained a number of HSEs and AP1-binding sites.
However, artificial promoters containing either multimer-
ized HSEs or AP1-binding sites were not activated by
EBNA3A,rulingout promoteractivationbya simple,generic
HSF mechanism. This suggests that EBNA3A activation was
either independent of the HSE/HSF-binding sequences or
that the precise promoter context (spacing and number of
sites) is essential in the observed response. This is consistent
with the specificity of the chaperones and co-chaperones that
are induced by EBNA3A. Although Hsp70B is activated by
HSF1 through HSE binding (He et al., 2003; Stanhill et al.,
2006), the lack of a generic HSF-mediated promoter
upregulation is consistent with the lack of a ‘blanket’ heat-
shock protein response to EBNA3A expression. For example,
microarray analysis showed no induction of related heat-
shock genes, such as Hsp60 or Hsp105, which are also
regulated byHSF1inmammalian cells (Trinkleinetal., 2004;
Supplementary Table S1, available in JGV Online).
EBNA3A, like the other EBNA3s, has no demonstrable
DNA-binding ability, but has been shown to associate with
DNA through the cellular DNA-binding adaptor protein
RBP-Jk (Cludts & Farrell, 1998). However, the minimal
Hsp70B promoter is devoid of any RBP-Jk-binding sites.
There is also no evidence that the association of EBNA3A
with CtBP (Hickabottom et al., 2002) contributed to the
observed induction of Hsp70B transcription, as both the
wild-type EBNA3A and the CtBP binding mutant activated
transcription to similar levels.
Co-IP experiments revealed that EBNA3A not only
upregulates, but also interacts with, Hsp70/70B9, Hsp40
and Bag3. From IP of Hsp40, we have found that both
EBNA3A and Hsp70 are co-precipitated following Western
blot with respective antibodies. The interaction of
Hsp40 with Hsp70 has been established previously
(Demand et al., 1998) and the results suggest the possibility
of a ternary Hsp70–Hsp40–EBNA3A complex. It has
been determined previously that both Hsp40 and Bag3
can bind Hsp70 proteins at distinct N- and C-terminal
binding domains, respectively (Demand et al., 1998;
Doong et al., 2003; Takayama et al., 1999). Given that
EBNA3A also binds Bag3, there is the potential for EBNA3A
to nucleate/participate in a chaperone–co-chaperone
complex.
Consistent with the hypothesis that EBNA3A forms a
complex with Hsp70 and partners following EBNA3A
expression in a stable, inducible cell line, Hsp70 redis-
tributes from the cytoplasm to the nucleus (Fig. 6c). The
shift in chaperone localization to the site of EBNA3A
function provides compelling evidence that EBNA3A and
Hsp70 interact and suggests that it is functionally
important. The interaction may not be linked exclusively
to protein folding; Hsp70 chaperones are also associated
with proteasome-mediated degradation, apoptosis and
antigen presentation (Beere & Green, 2001; Esser et al.,
2004; Mosser & Morimoto, 2004; Srivastava, 2002). At this
stage, we do not know which, if any, of these activities
relate to EBNA3A expression.
The predicted secondary structure of EBNA3A suggests
that the protein contains large regions of unstructured
(natively unfolded) polypeptide (Touitou et al., 2005). In
vitro degradation assays have shown that EBNA3A is
degraded readily by 20S proteasomes, but conversely, in
latently infected B cells, EBNA3A is very stable with little de
novo protein synthesis (Touitou et al., 2005). After primary
infection of resting B cells and the establishment of LCLs,
the level of Hsp70 is seen to increase (Fig. 5). The
interaction of EBNA3A with the Hsp70 chaperone complex
may act to ensure correct protein conformation of newly
synthesized proteins and as such protect EBNA3A from
proteasome degradation. This is consistent with Bag3, but
not Bag1, upregulation following EBNA3A expression
(Fig. 2d). Bag3 can abrogate Hsp70 complex and protea-
some-mediated degradation by acting after polyubiquitina-
tion has occurred (Doong et al., 2003). Hsp70 chaperone
complexes that assist proteasome-mediated degradation
typically form complexes containing Bag1 and ubiquitin
ligase proteins such as CHIP (reviewed by Esser et al.,
EBNA3A induces chaperone complex
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further interactions with chaperonins. EBNA3A has pre-
viously been shown to bind to the e subunit of the cytosolic
chaperonin TCP-1 ring complex (TRiC, also known as
CCT; Kashuba et al., 1999). It is unlikely, however, that all
EBNA3A associates with Hsp70 complexes or that all
Hsp70 complexes are protective. Hsp70 complexes have
been linked with activation of antigen-presenting cells,
cross-priming of antigen and processing of antigen for
presentation by the major histocompatibility complex
(reviewed by Srivastava, 2002), which may be important
for the prevention of EBV-driven disease and maintenance
of an asymptomatic infection.
EBV-positive Burkitt’s lymphoma-derived cells are rel-
atively resistant to cytotoxic drugs such as nocodazole,
taxol and ionomycin, and it has been suggested that the
EBNA3s may be involved in this phenotype (Kelly et al.,
2005; Leao et al., 2007). Bag family proteins, in addition to
modulating Hsp70 proteins, have been shown to work in
synergy with Bcl2 in overcoming Bax-induced and FasL/
Fas-mediated apoptosis (Antoku et al., 2001; Lee et al.,
1999; Takayama et al., 1995). Overexpression of Hsp70
alone can also prevent stress-induced apoptotic death
through a mechanism that may require its chaperone
function (Gabai et al., 1997; Mosser et al., 1997, 2000).
Hsp70 has been shown to affect apoptotic signalling
regulation, effector-molecule activation and events down-
stream of caspase activation (reviewed by Beere &
Green, 2001; Mosser & Morimoto, 2004). Although the
precise mechanism by which EBV enhances the survival of
B cells exposed to cytotoxic drugs is unknown, and other
viral factors could be responsible for the observed
phenotype, EBNA3A upregulation of Hsp70 and Bag3
could contribute to the observed reduction in programmed
cell death.
In summary, EBNA3A can specifically coordinate the
upregulation of a distinct subset of chaperones and co-
chaperones, and EBNA3A expression results in relocaliza-
tion of Hsp70 to the nucleus. EBNA3A activates transcrip-
tion of an Hsp70B promoter, but not of a promoter
containing multimerized HSEs, suggesting greater specifi-
city than a generic HSE/HSF response. Association of
EBNA3A with this subset of chaperones and co-chaperones
could ensure protein stability and may contribute to an
EBV-mediated anti-apoptotic phenotype and/or antigen
presentation.
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